Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.
Publication Type:
Journal ArticleSource:
Clinical cancer research : an official journal of the American Association for Cancer Research, Volume 15, Issue 14, p.4759-68 (2009)Keywords:
2009, Animals, Antigens, CD40, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Center-Authored Paper, Clinical Research Division, Clone Cells, Cytotoxicity, Immunologic, Female, Flow Cytometry Core Facility, Graft vs Host Disease, hematopoietic stem cell transplantation, Hematopoietic Stem Cells, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Leukocytes, Mononuclear, Male, MICE, Middle Aged, Minor Histocompatibility Antigens, Myeloablative Agonists, NIH 3T3 Cells, Shared Resources, T-Lymphocytes, Transplantation, Homologous, Treatment Outcome, VidarabineAbstract:
Allogeneic nonmyeloablative hematopoietic stem cell transplant (NM-HSCT) can result in durable remission of chronic lymphocytic leukemia (CLL). It is thought that the efficacy of NM-HSCT is mediated by recognition of tumor cells by T cells in the donor stem cell graft. We evaluated the development of CTLs specific for CLL after NM-HSCT to determine if their presence correlated with antitumor efficacy.
Doing Business with Arnold Library
Weintraub Building, B1-010
(206) 667-4314
library@fredhutch.org
More About Arnold Library
Quick Links
- ILLiad/ILL Form
- Journals List
- Ovid - Medline
- Web of Science
- Pubmed
- Libguides
- Library Catalog
- Researcher Profiles
- Library Affiliations & Memberships
- Fred Hutch Papers (Intranet)